Waldenstrom Macroglobulinemia — Trials

Waldenstrom Macroglobulinemia — Trials · CancerIndex

Clinical trials

Registered studies

308 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 59
Recruiting: 26
Ph III recruiting: 2
Growth YoY: —
Industry share: 39%
Top sponsor: Christian Buske
Termination share: 30.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07169331	A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia	active not recruiting	Phase 4	16	BeiGeneINDUSTRY	1	Aug 10, 2026	clinicaltrials
NCT07474961	BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.(BLOOD-dose)	not yet recruiting	Phase 4	400	Anne Louise Tølbøll SørensenOTHER	1	Mar 16, 2026